In this issue:
FOLFOX plus DC-CIK immunotherapy for CRC
Avelumab for refractory metastatic urothelial carcinoma
Hepatotoxicity risk in ICI-treated cancers
PD-L1 and its soluble form: a rationale for immunotherapy in NNKTL?
Multi-epitope vaccine from MMSA-1 and DKK1 for MM immunotherapy
Molecular profiling in signet ring CRC: rationale for genomic and ICI therapies
T-cells targeting tumour-associated antigens in radically operated NSCLC
HIV status and immune response to anal SCC: implications for immunotherapy
Tumour immune microenvironment and nivolumab efficacy in EGFRpositive NSCLC
IL-21 + PD-1/CTLA-4 blockade enhances antitumor immunity in mouse models
Please login below to download this issue (PDF)